Compare Otis Worldwide Corp (OTIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Otis Worldwide Corp trades at $70.61 (market cap $27.61B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: Otis Worldwide Corp pays a 2.36% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Otis Worldwide Corp nearer its low. Which is the better fit depends on your goals.
| OTIS | XBI | |
|---|---|---|
Market Cap | $27.61B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $100.99 | $164.28 |
52-Week Low | $69.34 | $85.16 |
Enterprise Value | $34.99B | — |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $71.95, down 2.04% recently, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates but showing strong service growth. Revenue trends are stable, with 2025 revenue at $14.43B and net income of $1.38B. Analyst consensus is a Buy with a $91.00 price target, implying significant upside. Recent news highlights modernization initiatives and Q2 earnings focus.
The outlook for OTIS is cautiously optimistic, with potential driven by service segment strength and strategic upgrades, but risks include margin pressures from tariffs and economic headwinds. Valuation at a P/E of 19.54 is reasonable, yet debt levels and recent earnings misses warrant monitoring. Institutional sentiment is mixed, with 38% Buy ratings offset by high debt-to-asset ratio of 75.54% as of 2025.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
